secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptiNose, Inc. (—)
CIK:        0001494650
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0001494650-24-000027
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptiNose amends debt covenants with BioPharma Credit, sets XHANCE sales targets through 2027
--------------------------------------------------------------------------------

- Minimum trailing 12-month XHANCE net sales/royalties set: $70M (Mar 31, 2024) rising to $160M (June 30, 2027).
- Make-whole premium on prepayments capped at $24M aggregate; formula changes based on prepayment timing relative to Nov 2024 and May 2026.
- All other terms of the A&R Note Purchase Agreement remain unchanged; no default exists as of amendment date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1494650/000149465024000027/0001494650-24-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1494650/000149465024000027/optn-20240308.htm
  HTML page:      https://secwatch.observer/filing/0001494650-24-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer